UCB Presents Long-Term CIMZIA Data in Crohn's Disease
CIMZIA maintained long-term response at stable doses
30-May-2007 -
UCB announced that new data presented at Digestive Disease Week 2007 (DDW) demonstrated long-term response and remission in Crohn's disease patients treated with CIMZIA(TM) (certolizumab pegol), the only Fc-free PEGylated, Fab' fragment anti-TNF.
The study, called PRECiSE 3 (P3), is a long-term ...
Crohn's disease
cytotoxicity
pain
+2